114 related articles for article (PubMed ID: 17192874)
1. BCAR1 expression in prostate cancer: association with 16q23 LOH status, tumor progression and EGFR/KAI1 staining.
Fromont G; Vallancien G; Validire P; Levillain P; Cussenot O
Prostate; 2007 Feb; 67(3):268-73. PubMed ID: 17192874
[TBL] [Abstract][Full Text] [Related]
2. Allelic loss at 16q23.2 is associated with good prognosis in high grade prostate cancer.
Fromont G; Valeri A; Cher M; Pontes JE; Vallancien G; Validire P; Latil A; Cussenot O
Prostate; 2005 Dec; 65(4):341-6. PubMed ID: 16015610
[TBL] [Abstract][Full Text] [Related]
3. Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss.
Dong JT; Suzuki H; Pin SS; Bova GS; Schalken JA; Isaacs WB; Barrett JC; Isaacs JT
Cancer Res; 1996 Oct; 56(19):4387-90. PubMed ID: 8813131
[TBL] [Abstract][Full Text] [Related]
4. Expression of the prostate cancer metastasis suppressor gene KAI1 in primary prostate cancers: a biphasic relationship with tumour grade.
Bouras T; Frauman AG
J Pathol; 1999 Aug; 188(4):382-8. PubMed ID: 10440748
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer.
Schlomm T; Kirstein P; Iwers L; Daniel B; Steuber T; Walz J; Chun FH; Haese A; Kollermann J; Graefen M; Huland H; Sauter G; Simon R; Erbersdobler A
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6579-84. PubMed ID: 18006757
[TBL] [Abstract][Full Text] [Related]
6. Cyclooxygenase-2 expression is dependent upon epidermal growth factor receptor expression or activation in androgen independent prostate cancer.
Jia RP; Xu LW; Su Q; Zhao JH; Li WC; Wang F; Xu Z
Asian J Androl; 2008 Sep; 10(5):758-64. PubMed ID: 18645679
[TBL] [Abstract][Full Text] [Related]
7. Decreased expression of KAI1/CD82 metastasis suppressor gene is associated with loss of heterozygosity in melanoma cell lines.
Kim YI; Shin MK; Lee JW; Chung JH; Lee MH
Oncol Rep; 2009 Jan; 21(1):159-64. PubMed ID: 19082457
[TBL] [Abstract][Full Text] [Related]
8. Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome.
Wang KL; Wu TT; Choi IS; Wang H; Resetkova E; Correa AM; Hofstetter WL; Swisher SG; Ajani JA; Rashid A; Albarracin CT
Cancer; 2007 Feb; 109(4):658-67. PubMed ID: 17211865
[TBL] [Abstract][Full Text] [Related]
9. BCAR1 expression improves prediction of biochemical reccurence after radical prostatectomy.
Fromont G; Rozet F; Cathelineau X; Ouzzane A; Doucet L; Fournier G; Cussenot O
Prostate; 2012 Sep; 72(12):1359-65. PubMed ID: 22241677
[TBL] [Abstract][Full Text] [Related]
10. High epidermal growth factor receptor expression in metastatic colorectal cancer lymph nodes may be more prognostic of poor survival than in primary tumor.
Deng Y; Kurland BF; Wang J; Bi J; Li W; Rao S; Lan P; Lin T; Lin E
Am J Clin Oncol; 2009 Jun; 32(3):245-52. PubMed ID: 19451802
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor (EGFR) expression in prostatic adenocarcinoma after hormonal therapy: a fluorescence in situ hybridization and immunohistochemical analysis.
Marks RA; Zhang S; Montironi R; McCarthy RP; MacLennan GT; Lopez-Beltran A; Jiang Z; Zhou H; Zheng S; Davidson DD; Baldridge LA; Cheng L
Prostate; 2008 Jun; 68(9):919-23. PubMed ID: 18409189
[TBL] [Abstract][Full Text] [Related]
12. Expression of epidermal growth factor receptor in relation to BRCA1 status, basal-like markers and prognosis in breast cancer.
Arnes JB; Bégin LR; Stefansson I; Brunet JS; Nielsen TO; Foulkes WD; Akslen LA
J Clin Pathol; 2009 Feb; 62(2):139-46. PubMed ID: 18682421
[TBL] [Abstract][Full Text] [Related]
13. Allelic loss of 16q23.2-24.2 is an independent marker of good prognosis in primary breast cancer.
Hansen LL; Yilmaz M; Overgaard J; Andersen J; Kruse TA
Cancer Res; 1998 May; 58(10):2166-9. PubMed ID: 9605761
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor (ErbB1) expression in prostate cancer progression: correlation with androgen independence.
Shah RB; Ghosh D; Elder JT
Prostate; 2006 Sep; 66(13):1437-44. PubMed ID: 16741920
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of KAI1 mRNA in localised prostate cancer and its bony metastases does not correlate with p53 overexpression.
Jackson P; Ow K; Yardley G; Delprado W; Quinn DI; Yang JL; Russell PJ
Prostate Cancer Prostatic Dis; 2003; 6(2):174-81. PubMed ID: 12806379
[TBL] [Abstract][Full Text] [Related]
16. Gene amplification and mutation analysis of epidermal growth factor receptor in hormone refractory prostate cancer.
Cho KS; Lee JS; Cho NH; Park K; Ham WS; Choi YD
Prostate; 2008 Jun; 68(8):803-8. PubMed ID: 18302229
[TBL] [Abstract][Full Text] [Related]
17. Preoperative plasma HER2 and epidermal growth factor receptor for staging and prognostication in patients with clinically localized prostate cancer.
Shariat SF; Bensalah K; Karam JA; Roehrborn CG; Gallina A; Lotan Y; Slawin KM; Karakiewicz PI
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5377-84. PubMed ID: 17875766
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer.
Dihge L; Bendahl PO; Grabau D; Isola J; Lövgren K; Rydén L; Fernö M
Breast Cancer Res Treat; 2008 May; 109(2):255-62. PubMed ID: 17636398
[TBL] [Abstract][Full Text] [Related]
19. Involvement of decreased Galectin-3 expression in the pathogenesis and progression of prostate cancer.
Merseburger AS; Kramer MW; Hennenlotter J; Simon P; Knapp J; Hartmann JT; Stenzl A; Serth J; Kuczyk MA
Prostate; 2008 Jan; 68(1):72-7. PubMed ID: 18008332
[TBL] [Abstract][Full Text] [Related]
20. High BCAR1 expression is associated with early PSA recurrence in ERG negative prostate cancer.
Heumann A; Heinemann N; Hube-Magg C; Lang DS; Grupp K; Kluth M; Minner S; Möller-Koop C; Graefen M; Heinzer H; Tsourlakis MC; Wilczak W; Wittmer C; Jacobsen F; Huland H; Simon R; Schlomm T; Sauter G; Steurer S; Lebok P; Hinsch A
BMC Cancer; 2018 Jan; 18(1):37. PubMed ID: 29304771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
